Although it was previously shown that the ISR might potentiate the posttranscriptional production of PD-L1 in cancer cells (68), the mechanism by which the ISR suppresses PD-L1 levels in other disease contexts remains largely unexplored. This evidence concerns the gene CD274 and cancer.